Genes help explain GLP‑1 response

Glucagon-like peptide 1 is a gut hormone that tells your brain and stomach that food has arrived, so drugs that mimic it can slow digestion and cut appetite for weeks at a time. Medicines like semaglutide and tirzepatide use that signal, but people on the same dose can have very different results. (nature.com) Doctors have seen that split in clinics for years: some patients lose less than 5% of their body weight, while others lose more than 20%, and side effects like nausea and vomiting also vary a lot from person to person. That gap pushed researchers to ask whether part of the difference is written into DNA before the first injection. (scientificamerican.com) To test that, researchers ran a genome-wide association study, which is a giant comparison of DNA markers across many people to see which markers travel with a trait. In this case, the team analyzed self-reported weight loss and side effects from 27,885 people who had taken glucagon-like peptide 1 receptor agonist drugs. (nature.com) The clearest signal showed up in a gene called glucagon-like peptide 1 receptor, which is the cellular lock that these drugs are designed to fit. One protein-changing variant in that gene was linked to greater weight loss, with about 0.76 kilograms of extra loss for each copy of the effect version a person carried. (nature.com) A second signal showed up in glucose-dependent insulinotropic polypeptide receptor, which is another hormone receptor involved in appetite and metabolism. Variants there were tied less to extra weight loss and more to gastrointestinal side effects, including nausea. (nature.com) That receptor link is especially interesting because tirzepatide does not only act on glucagon-like peptide 1 pathways. Tirzepatide also targets glucose-dependent insulinotropic polypeptide, so a gene affecting that receptor could help explain why some stomachs tolerate these drugs better than others. (nature.com) The study did not say genes are destiny. The Nature news report says DNA explained only part of the variation, which leaves room for dose, diet, other medicines, gut biology, and how long someone stays on treatment to shape the outcome too. (nature.com) The data also came from 23andMe participants who reported their own drug use, weight change, and symptoms, which makes the sample unusually large but not as clean as a tightly controlled clinical trial. The paper’s authors say the findings still need follow-up in more diverse groups and in studies that directly track prescriptions and measured weight over time. (nature.com) What this points toward is a future where a doctor could use a genetic report the way they already use kidney labs or blood pressure readings: not to decide everything, but to make a better guess before treatment starts. The 23andMe Research Institute said it has already folded the variants into a broader prediction model that also includes demographic and clinical factors. (mediacenter.23andme.com) For now, the practical takeaway is narrower than the hype. This paper does not tell any one patient whether semaglutide or tirzepatide will definitely work, but it does show that the same DNA differences that change how a drug hits its target can also change how much weight comes off and how rough the nausea feels. (nature.com)